The news is directly about Ascendis Pharma and is likely to influence investor sentiment. The lowering of the price target might be seen as a negative signal, but the maintenance of the Overweight rating indicates that the analyst still sees the stock as a good investment. The net impact on the stock price in the short term is uncertain, hence the neutral score.